The Delhi High Court has granted an interim injunction to Mankind Pharma Limited, restraining the defendants from using trademarks that are deceptively similar to Mankind’s trademarks, including ‘KIND’, ‘FENDIKIND’, ‘ZENKIND’, and ‘DIZIKIND’. The court held that the defendants’ products, such as ‘FENKIND’, ‘DICKIND’, ‘LONOKIND’, and ‘CHIMOKIND’, were identical or deceptively similar to Mankind’s products and amounted to trademark infringement.
Mankind Pharma Limited is a well-known pharmaceutical company that has acquired tremendous goodwill and reputation in India and globally. The company is the registered proprietor of several trademarks, including ‘FENDIKIND’, ‘ZENKIND’, and ‘DIZIKIND’, and its trademarks ‘MANKIND’ and ‘KIND’ have been declared as well-known trademarks by the Registrar of Trade Marks.
The court noted that Mankind had established long and continuous use of its trademark, which had been registered since 1995. The use of Mankind’s trademark by the defendant was seen as an attempt to ride on the established goodwill and reputation of Mankind, and was thus a prima facie dishonest attempt to confuse the market.
The court opined that Mankind, being the prior user and adopter of the mark ‘KIND’, was entitled to protection. The court held that Mankind had made out a prima facie case for grant of an ex-parte ad-interim injunction, and that the balance of convenience was in favor of Mankind and against the defendant.
As a result, the court restrained the defendant from manufacturing, selling, or advertising products under the marks ‘DICKIND’, ‘LONOKIND’, ‘FENKIND’, and ‘CHIMOKIND’, or any other trademark that may be identical or deceptively similar to Mankind’s trademarks. The matter has been listed for further hearing on January 28, 2026.
The advocates who appeared in this case were Ankur Sangal, Ankit Arvind, Nidhi Pathak, and Rishab Rao for the plaintiff, Mankind Pharma Limited. The court’s decision is a significant victory for Mankind Pharma Limited, and underscores the importance of protecting intellectual property rights in the pharmaceutical industry.